The DOI matches its Crossref record; the references it cites are not checked yet.
Discovery and characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules
Open accessPublished version of a preprint
Abstract
p53 is known as the guardian of the genome and is one of the most important tumor suppressors. It is inactivated in most tumors, either via tumor protein p53 (TP53) gene mutation or copy number amplification of key negative regulators, e.g., mouse double minute 2 (MDM2). Compounds that bind to the MDM2 protein and disrupt its interaction with p53 restore p53 tumor suppressor activity, thereby promoting cell cycle arrest and apoptosis. Previous clinical experience with MDM2–p53 protein–protein interaction antagonists (MDM2–p53 antagonists) has demonstrated that thrombocytopenia and neutropenia represent on-target dose-limiting toxicities that might restrict their therapeutic utility. Dosing less frequently, while maintaining efficacious exposure, represents an approach to mitigate toxicity and improve the therapeutic window of MDM2–p53 antagonists. However, to achieve this, a molecule possessing excellent potency and ideal pharmacokinetic properties is required. Here, we present the discovery and characterization of brigimadlin (BI 907828), a novel, investigational spiro-oxindole MDM2–p53 antagonist. Brigimadlin exhibited high bioavailability and exposure, as well as dose-linear pharmacokinetics in preclinical models. Brigimadlin treatment restored p53 activity and led to apoptosis induction in preclinical models of TP53 wild-type, MDM2-amplified cancer. Oral administration of brigimadlin in an intermittent dosing schedule induced potent tumor growth inhibition in several TP53 wild-type, MDM2-amplified xenograft models. Exploratory clinical pharmacokinetic studies (NCT03449381) showed high systemic exposure and a long plasma elimination half-life in patients with cancer who received oral brigimadlin. These findings support the continued clinical evaluation of brigimadlin in patients with MDM2-amplified cancers, such as dedifferentiated liposarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 5. Brigimadlin efficacy in mouse xenograft models. Tumor growth curves (mean ± SEM) for brigimadlin in A, MDM2-amplified SJSA-1 osteosarcoma CDX model [MDM2 CN (qPCR) = 55]; (B), MDM2-amplified undifferentiated pleomorphic sarcoma (SA3283) PDX model [MDM2 CN (qPCR) = 132]; (C), MDM2-amplified lung squamous cell carcinoma (LU0861) PDX model [MDM2 CN (qPCR) = 20]; (D), MDM2-amplified lung squamous cell carcinoma (LU6903) PDX model [MDM2 CN (qPCR) = 19]. Ten mice per treatment group were randomized to brigimadlin 2 mg/kg p.o. QW for 2 weeks (SJSA-1 and SA3283), 3 weeks (LU0861), or 5 weeks (LU6903)], respectively, or to vehicle. BID, twice daily; CDX, cell line-derived xenograft; CN, copy number; PDX, patient-derived xenograft; p.o., oral; QW, once per week; SEM, standard error of the mean. P-values (brigimadlin vs. vehicle control group) of <0.05 are regarded as statistically significant.](https://figures.cochat.ai/paper-figures/c38b758f34a145589e3c2019735f4769/discovery-and-characterization-of-brigimadlin-a-novel-and-highly-potent-mdm2-p53-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Brigimadlin is distinguished by its exceptionally high potency.10”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 43 · Cited by 18
Research works printed but not linked: 3
- Tickle, 2018, STARANISO
- Bricogne, 2017, BUSTER
- Allard, 2020, Exposure–macrophage inhibitory cytokine-1 (MIC-1) response analysis of the MDM2 antagonist KRT-232 in patients with advanced solid tumors, multiple myeloma, or acute myeloid leukemia, HemaSphere, 4, 212
Metadata
- Authors
- Gollner, A., Rudolph, D., Weyer-Czernilofsky, U., Baumgartinger, R., Jung, P., Weinstabl, H., Ramharter, J., Grempler, R., Quant, J., Rinnenthal, J., Pérez Pitarch, A., Golubovic, B., Gerlach, D., Bader, G., Wetzel, K., Otto, S., Mandl, C., Boehmelt, G., McConnell, D. B., Kraut, N., & Sini, P.
- Affiliations
- Boehringer Ingelheim (Austria) (AT)
- Boehringer Ingelheim (United States) (US)
- 1Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria.
- 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany.
- 4Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Gollner, Andreas
- Sini, Patrizia
- ORCID
- Gollner, Andreas
- Rudolph, Dorothea
- Weyer-Czernilofsky, Ulrike
- Baumgartinger, Rosa
- Jung, Peter
- Weinstabl, Harald
- Ramharter, Jürgen
- Grempler, Rolf
- Quant, Jens
- Rinnenthal, Jörg
- Pérez Pitarch, Alejandro
- Golubovic, Bojana
- Gerlach, Daniel
- Bader, Gerd
- Wetzel, Kristiane
- Otto, Sebastian
- Mandl, Christian
- Boehmelt, Guido
- McConnell, Darryl B.
- Kraut, Norbert
- Sini, Patrizia
- Venue
- Molecular Cancer Therapeutics
- Published
- 2024-09-11
- Volume
- 23
- Issue
- 12
- Pages
- 1689-1702
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- PMC
- PMC11612618
- OpenAlex
- W4402438635
- Cited by
- 18
- References
- 43
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 1
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Cancer Therapeutics (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by-nc-nd)
- Funders
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- brigimadlin, BI 907828, MDM2-p53 antagonist, MDM2 amplification, spirooxindoles, intermittent dosing, pharmacokinetics, bioavailability, dose-limiting toxicity, thrombocytopenia, neutropenia, dedifferentiated liposarcoma, tumor growth inhibition, apoptosis
- MeSH terms
- Animals, Antineoplastic Agents, Female, Humans, Indoles, Male, Spiro Compounds, Tumor Suppressor Protein p53, Apoptosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, Rats, Proto-Oncogene Proteins c-mdm2, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules. https://app.cochat.ai/papers/10.1158/1535-7163.mct-23-0783
- The paper
- Gollner, A., Rudolph, D., Weyer-Czernilofsky, U., Baumgartinger, R., Jung, P., Weinstabl, H., Ramharter, J., Grempler, R., Quant, J., Rinnenthal, J., Pérez Pitarch, A., Golubovic, B., Gerlach, D., Bader, G., Wetzel, K., Otto, S., Mandl, C., Boehmelt, G., McConnell, D. B., . . . Sini, P. (2024). Discovery and characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-23-0783
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.